Talking about Lymphoma at Work

Talking about lymphoma can be difficult and you may not want to tell your colleagues in order to keep one area of your life normal. This is a good coping strategy for some
people. Sometimes, however, the effects of cancer treatment e.g. your hair falling out and the need to take time off, may make it impossible not to tell your colleagues.

By letting others know, they will be able to offer you support and will understand if your behavior is a little out of character. Ask your employer for a private meeting and then if you wish, you can ask for the details to be kept confidential so you can choose who to tell and when.

Verve, a magazine devoted to those living with lymphatic cancer, shares these suggestions. Everyone’s experience is different – your fatigue may be very mild and does not interfere with their work, whereas others find it very disruptive and struggle to complete everyday tasks. If you find fatigue is a problem, your employer may be able to help you by:

Changing your duties

Setting realistic deadlines that you can manage

Asking colleagues to support you by helping with some of your work

Finding you a lighter workload if your job involves physical exertion or heavy lifting

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap